Wall Street Zen upgraded shares of MiMedx Group (NASDAQ:MDXG – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.
Several other brokerages also recently weighed in on MDXG. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 target price on shares of MiMedx Group in a research note on Monday, August 17th. Craig Hallum raised their price target on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Seaport Research Partners downgraded shares of MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of MiMedx Group in a report on Thursday, August 13th. Finally, Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a research report on Monday, August 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and an average target price of $8.57.
Check Out Our Latest Report on MiMedx Group
MiMedx Group Price Performance
MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The company had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. On average, analysts forecast that MiMedx Group will post -0.1 EPS for the current fiscal year.
Institutional Trading of MiMedx Group
Several institutional investors have recently made changes to their positions in MDXG. SkyView Investment Advisors LLC raised its position in shares of MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares during the period. Rafferty Asset Management LLC grew its position in MiMedx Group by 4.6% during the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after acquiring an additional 3,064 shares during the period. Aviva PLC grew its position in MiMedx Group by 4.7% during the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock valued at $482,000 after acquiring an additional 3,211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after acquiring an additional 4,296 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.
MiMedx Group Company Profile
MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.
MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.
Read More
- Five stocks we like better than MiMedx Group
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
